🔴 CRSP Slips 4.1% Despite FDA Label Expansion for CASGEVY and Analyst Buy Reiteration

CRSP is trading 4.1% down today at $58.31, pulling back from its recent rally. This comes despite H.C. Wainwright reiterating a Buy rating and an $80 price target following the FDA's expansion of CASGEVY's label to include patients aged two years and older. The broader market is also weak due to rising geopolitical tensions and ahead of today's FOMC minutes release.